• Je něco špatně v tomto záznamu ?

Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial

M. Joubert, V. Opigez, B. Pavlikova, L. Peyro Saint Paul, N. Jeandidier, AR. Briant, JJ. Parienti, Y. Reznik

. 2021 ; 23 (2) : 374-381. [pub] 20201030

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc21026109

AIM: To assess the safety and efficacy of the short-acting glucagon-like peptide-1 receptor agonist exenatide on a population of patients with type 2 diabetes (T2D) mostly treated with continuous subcutaneous insulin injection (CSII). MATERIALS AND METHODS: A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted. Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo. RESULTS: A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18). CSII treatment was used by 75% and 89% of patients of the exenatide and placebo groups, respectively. At 6 months, the change in HbA1c was -0.62% ± 0.94% and 0.08% ± 0.81% in the exenatide and placebo groups, respectively (difference, -0.70%; 95% CI [-1.24%; -0.15%], P = .014); body weight and body mass index decreased in the exenatide group (-2.55 ± 3.25 kg and -1.00 ± 1.31 kg/m2 ) and increased in the placebo group (1.29 ± 2.82 kg and 0.46 ± 1.16 kg/m2 ) (observed difference, -3.85 and -1.45, respectively, both P < .001); the postdinner capillary blood glucose value was lower in the exenatide group compared with the placebo group (162.4 ± 80.5 vs. 259.1 ± 94.4 mg/dL, respectively; observed difference, -96.7, P < .01). Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group. CONCLUSIONS: Although we failed to reach our planned sample size, the addition of exenatide treatment 10 μg BID SC in T2D patients with uncontrolled HbA1c despite an intensified insulin regimen, resulted in a significant reduction of HbA1c and body weight with a good overall safety profile and acceptance.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21026109
003      
CZ-PrNML
005      
20211026133213.0
007      
ta
008      
211013s2021 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/dom.14225 $2 doi
035    __
$a (PubMed)33043591
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Joubert, Michael $u Diabetes Care Unit, Caen University Hospital, Caen, France $u Unicaen, Caen, France
245    10
$a Efficacy and safety of exenatide as add-on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double-blind trial / $c M. Joubert, V. Opigez, B. Pavlikova, L. Peyro Saint Paul, N. Jeandidier, AR. Briant, JJ. Parienti, Y. Reznik
520    9_
$a AIM: To assess the safety and efficacy of the short-acting glucagon-like peptide-1 receptor agonist exenatide on a population of patients with type 2 diabetes (T2D) mostly treated with continuous subcutaneous insulin injection (CSII). MATERIALS AND METHODS: A phase 2/3, multicentre, randomized, parallel-group, double-blind, placebo-controlled, 6-month trial was conducted. Patients were randomized to receive subcutaneous (SC) injections of exenatide (10 μg BID) or matched placebo. RESULTS: A total of 46 patients with T2D and elevated HbA1c were randomized (42% of the planned sample size): exenatide (n = 28) and placebo (n = 18). CSII treatment was used by 75% and 89% of patients of the exenatide and placebo groups, respectively. At 6 months, the change in HbA1c was -0.62% ± 0.94% and 0.08% ± 0.81% in the exenatide and placebo groups, respectively (difference, -0.70%; 95% CI [-1.24%; -0.15%], P = .014); body weight and body mass index decreased in the exenatide group (-2.55 ± 3.25 kg and -1.00 ± 1.31 kg/m2 ) and increased in the placebo group (1.29 ± 2.82 kg and 0.46 ± 1.16 kg/m2 ) (observed difference, -3.85 and -1.45, respectively, both P < .001); the postdinner capillary blood glucose value was lower in the exenatide group compared with the placebo group (162.4 ± 80.5 vs. 259.1 ± 94.4 mg/dL, respectively; observed difference, -96.7, P < .01). Hypoglycaemic risk, quality of life and overall safety were not different between the groups, apart from the expected occurrence of digestive effects in the exenatide group. CONCLUSIONS: Although we failed to reach our planned sample size, the addition of exenatide treatment 10 μg BID SC in T2D patients with uncontrolled HbA1c despite an intensified insulin regimen, resulted in a significant reduction of HbA1c and body weight with a good overall safety profile and acceptance.
650    _2
$a krevní glukóza $7 D001786
650    12
$a diabetes mellitus 2. typu $x farmakoterapie $7 D003924
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a exenatid $7 D000077270
650    _2
$a glykovaný hemoglobin $x analýza $7 D006442
650    _2
$a lidé $7 D006801
650    _2
$a hypoglykemika $x škodlivé účinky $7 D007004
650    _2
$a inzulin $7 D007328
650    _2
$a kvalita života $7 D011788
650    _2
$a výsledek terapie $7 D016896
650    _2
$a živočišné jedy $x škodlivé účinky $7 D014688
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Opigez, Victoria $u Diabetes Care Unit, Caen University Hospital, Caen, France
700    1_
$a Pavlikova, Barbora $u First Department of Internal Medicine, Charles University Hospital in Pilsen, Pilsen, Czech Republic $u Charles University, Faculty of Medicine in Pilsen, Pilsen, Czech Republic
700    1_
$a Peyro Saint Paul, Laure $u Clinical Research Unit, Caen University Hospital, Caen, France
700    1_
$a Jeandidier, Nathalie $u Diabetes Care Unit, Strasbourg University Hospital, Strasbourg, France
700    1_
$a Briant, Anaïs R $u Clinical Research Unit, Caen University Hospital, Caen, France
700    1_
$a Parienti, Jean-Jacques $u Unicaen, Caen, France $u Clinical Research Unit, Caen University Hospital, Caen, France
700    1_
$a Reznik, Yves $u Diabetes Care Unit, Caen University Hospital, Caen, France $u Unicaen, Caen, France
773    0_
$w MED00005425 $t Diabetes, obesity & metabolism $x 1463-1326 $g Roč. 23, č. 2 (2021), s. 374-381
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33043591 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20211013 $b ABA008
991    __
$a 20211026133219 $b ABA008
999    __
$a ok $b bmc $g 1714965 $s 1146616
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 23 $c 2 $d 374-381 $e 20201030 $i 1463-1326 $m Diabetes, obesity and metabolism $n Diabetes Obes Metab $x MED00005425
LZP    __
$a Pubmed-20211013
Zpět

Najít záznam

Citační ukazatele

Možnosti archivace